ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: 0274 • ACR Convergence 2024

    Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout

    Yana Pryymachenko1, Ross Wilson1, Haxby Abbott1, Nicola Dalbeth2 and Lisa Stamp3, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
  • Abstract Number: 1071 • ACR Convergence 2024

    Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints

    Anouchka Lewis1, John Stack2, Oisin Corish2, Callum Swift2, Tomás Breslin2, Frank Lyons2, Eavan Muldoon2, Cian McDermott2, Sharon Cowley2, Helina Alemayehu2, Oliver Boughton2, Khaled Taha2 and Geraldine McCarthy2, 1The Mater Misericordiae University Hospital, Dublin, Ireland, 2Mater Misericordiae University Hospital, Dublin, Ireland

    Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
  • Abstract Number: 1099 • ACR Convergence 2024

    Distinct Metabolomic Signatures of Insulinemia and Incident Gout Risk: A Prospective Cohort Study Among Women

    Sharan Rai1, Hyon K. Choi2, Chio Yokose1 and Natalie McCormick1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Gout and the metabolic syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate levels in physiologic studies, and a Mendelian Randomization…
  • Abstract Number: 2006 • ACR Convergence 2024

    Gout Flares After Stopping Anti-inflammatory Prophylaxis During the Early Phases of Urate-Lowering Therapy

    Lisa Stamp1, Chris Frampton1, James O'Dell2, Ted Mikuls2, Jeff Newcomb2 and Nicola Dalbeth3, 1University of Otago, Christchurch, Christchurch, New Zealand, 2University of Nebraska Medical Center, Omaha, NE, 3University of Auckland, Auckland, New Zealand

    Background/Purpose: Anti-inflammatory prophylaxis is recommended during the initial period of urate-lowering therapy (ULT) as gout flares are common during this time. The aim of this…
  • Abstract Number: 2022 • ACR Convergence 2024

    Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies

    Natalie McCormick1, Chio Yokose2, Leo Lu3, Sharan Rai1, Gregory Challener1 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
  • Abstract Number: 0275 • ACR Convergence 2024

    Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation

    Sadiq Umar1 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago

    Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
  • Abstract Number: 1073 • ACR Convergence 2024

    Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting

    Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA

    Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
  • Abstract Number: 1100 • ACR Convergence 2024

    Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study

    Chio Yokose1, Tristan Pascart2, Mangun Randhawa3, Padraic Kennedy4, Christoph Schwabl5, saiajay chigurupati3, Bohang Jiang3, Leo Lu6, Julia Held5, Gerlig Widmann5, F. Joseph Simeone3, Brian Ghoshhajra3, Adnan Sheikh4, Kamran Shojania4, Gudrun Feuchtner5, Andrea Klauser5, Savvas Nicolaou4, Jean-François Budzik2, Fabio Becce7 and Hyon K. Choi8, 1Massachusetts General Hospital, Waltham, MA, 2Lille Catholic University, Lille, France, 3Massachusetts General Hospital, Boston, MA, 4Vancouver General Hospital, Vancouver, Canada, 5Medical University Innsbruck, Innsbruck, Austria, 6Arthritis Research Canada, Vancouver, BC, Canada, 7Lausanne University Hospital (CHUV), Lausanne, Switzerland, 8Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Prior dual-energy CT (DECT) studies have suggested that monosodium urate (MSU) crystals may be present in the coronary arteries of patients with gout. However,…
  • Abstract Number: 2007 • ACR Convergence 2024

    Relationship Between Gout Flare Burden and Patient-Reported Outcome Following Allopurinol Initiation

    Lisa Stamp1, Chris Frampton1, Sarah Stewart2, Keith Petrie3, N Lawrence Edwards4, Angelo Gaffo5 and Nicola Dalbeth3, 1University of Otago, Christchurch, Christchurch, New Zealand, 2Auckland University of Technology, Auckland, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Florida, Florida, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Gout flares are the most important clinical feature for people who have the disease. Given currently available treatment possibilities and limitations, low disease activity…
  • Abstract Number: 2023 • ACR Convergence 2024

    A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

    Frank Fan1, Riyong Liu1 and Yu Wang2, 1Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), 2Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)

    Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
  • Abstract Number: 0277 • ACR Convergence 2024

    Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation

    Jennifer Lee1 and Ah Young Choi2, 1seoul st mary's hospital, Seoul, South Korea, 2The Cactholic University of Korea, Seoul, Republic of Korea

    Background/Purpose: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases. Acute gout is initiated by IL-1β produced by monosodium…
  • Abstract Number: 1083 • ACR Convergence 2024

    Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout

    Rachel Murdoch1, Lene Terslev2, Julia Martin3, Borislav Mihov1, Gregory Gamble1, Søren Torp-Pedersen4, Anne Horne1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, 3Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, 4Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization…
  • Abstract Number: 1101 • ACR Convergence 2024

    The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population

    Chio Yokose1, Leo Lu2, Sharan Rai3, Natalie McCormick3 and Hyon K. Choi4, 1Massachusetts General Hospital, Waltham, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Gout and chronic kidney disease (CKD) are both common conditions which are associated with high morbidity and mortality and often coexist. We sought to…
  • Abstract Number: 2008 • ACR Convergence 2024

    A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)

    ullrich schwertschlag1, william dongfang Shi2, rOBERT PERRY3, Kwabena Ayesu4, rOY WU5, jerry liu6, JinSying Lin7 and Adam Jin8, 1Atombio Science, PALO ALTO, CA, 2Jiangsu Atom Bioscience,, Suzhou, Jiangsu, China (People's Republic), 3Panax Clin Res, Miami Lakes, FL, 4OMEGARLLC, ORLANDO, FL, 5Atom Bioscience, SAN FRANCISCO, CA, 6atombio, San Diego, CA, 7Biostatconsulting, Wuzhong, Suzhou, Jiangsu, China (People's Republic), 8atom biosciences, Wuzhong, Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: In this open-label Phase 1 study, 22 participants were enrolled in 3 cohorts, 10 participants with normal kidney function (eGFR ≥90 ml/min/1.73m2 and no…
  • 1
  • 2
  • 3
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology